Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
168.52
+4.34 (2.64%)
At close: Jun 26, 2026, 4:00 PM EDT
167.83
-0.69 (-0.41%)
After-hours: Jun 26, 2026, 7:49 PM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 24 analysts with 12-month price forecasts for Neurocrine Biosciences stock have an average target of 188.79, with a low estimate of 144 and a high estimate of 246. The average target predicts an increase of 12.03% from the current stock price of 168.52.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock from 29 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 20 | 20 | 19 | 20 | 21 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 28 | 28 | 27 | 28 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Buy Maintains $181 | Buy | Maintains | $181 | +7.41% | Jun 16, 2026 |
| Citi | Citi | Buy Maintains $246 | Buy | Maintains | $246 | +45.98% | Jun 16, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 2, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Initiates $213 | Buy | Initiates | $213 | +26.39% | Jun 2, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $180 → $183 | Buy | Maintains | $180 → $183 | +8.59% | May 29, 2026 |
Financial Forecast
Revenue This Year
3.77B
from 2.86B
Increased by 31.95%
Revenue Next Year
4.49B
from 3.77B
Increased by 18.96%
EPS This Year
10.39
from 6.39
Increased by 62.67%
EPS Next Year
12.68
from 10.39
Increased by 21.94%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.0B | 5.4B | |
| Avg | 3.8B | 4.5B | |
| Low | 3.4B | 3.9B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 38.9% | 42.1% | |
| Avg | 32.0% | 19.0% | |
| Low | 19.7% | 3.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.37 | 20.06 | |
| Avg | 10.39 | 12.68 | |
| Low | 8.27 | 8.54 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 171.8% | 93.0% | |
| Avg | 62.7% | 21.9% | |
| Low | 29.4% | -17.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.